Gauri Chaturvedi
- PG Student, Department of Biotechnology, Amity University, Noida, Uttar Pradesh, India
Abstract
Recombinant insulin, a revolutionary product of biotechnology, has transformed the landscape of diabetes treatment. Developed through genetic engineering techniques, recombinant insulin offers a safer, more consistent alternative to traditional animal-derived insulin. Its production involves the insertion of the human insulin gene into host organisms such as Escherichia coli or Saccharomyces cerevisiae, which serve as efficient factories for insulin synthesis.
Recombinant insulin is used to treat diabetic patients who are allergic to beef or pork insulin. This form of insulin is made from recombinant DNA technology that is similar to human insulin. As a consequence, allergy reactions in humans are not very severe. This insulin produced is manufactured and then purified. It is a boon for diabetic patients.
One of the key advantages of recombinant insulin lies in its molecular identity to endogenous human insulin, ensuring improved efficacy and reduced risk of adverse reactions. Additionally, recombinant insulin enables precise dosing and customization of treatment regimens through the development of insulin analogs with varied pharmacokinetic properties.
The widespread adoption of recombinant insulin has significantly enhanced diabetes management outcomes, leading to better glycemic control and decreased risk of complications. Furthermore, its scalable production and cost-effectiveness have contributed to increased accessibility to essential insulin therapy worldwide.
In conclusion, recombinant insulin represents a pivotal advancement in diabetes care, offering a potent combination of biotechnological innovation and medical progress. Further research and development in this area will improve insulin therapy, which looks set to ultimately improve the lives of millions of people with diabetes
Keywords: Insulin, Diabetes, Recombinant DNA technology, Recombinant insulin, Genetic engineering.
[This article belongs to International Journal of Genetic Modifications and Recombinations(ijgmr)]
Browse Figures
References
- How insulin is made – material, manufacture, history, used, parts, components, structure, steps, product. Madehow.com. 2014. Available from: https://www.madehow.com/Volume-7/Insulin.html#ixzz5Irfwu2um
- Siew YY, Zhang W. Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies. Bioresources and Bioprocessing. 2021 Dec;8:1-27.
- Flickinger MC, editor. Downstream industrial biotechnology: recovery and purification. John Wiley & Sons; 2013 Jul 17.
- Bhoria S, Yadav J, Yadav H, Chaudhary D, Jaiwal R, Jaiwal PK. Current advances and future prospects in production of recombinant insulin and other proteins to treat diabetes mellitus. Biotechnology Letters. 2022 Jun;44(5):643-69.
- sgugenetics / Advantages and Disadvantages of Insulin produced by Biotechnology. Pbworks.com. 2024. Available from: http://sgugenetics.pbworks.com/w/page/31871872/Advantages%20and%20Disadvantages%20of%20Insulin%20produced%20by%20Biotechnology
- Allen D, Ruan CH, King B, Ruan KH. Recent advances and near future of insulin production and therapy. Future Medicinal Chemistry. 2019 Aug;11(13):1513-7.
- Redwan ER, Matar SM, El‐Aziz GA, Serour EA. Synthesis of the human insulin gene: protein expression, scaling up and bioactivity. Preparative Biochemistry and Biotechnology. 2007 Dec 1;38(1):24-39.
- Antibiotic production process. Jpabs.org. 2024. Available from: https://jpabs.org/misc/antibiotic-production-process.html
- Landgraf W, Sandow J. Recombinant human insulins–clinical efficacy and safety in diabetes therapy. European endocrinology. 2016 Mar;12(1):12.
- Alyas J, Rafiq A, Amir H, Khan SU, Sultana T, Ali A, Hameed A, Ahmad I, Kazmi A, Sajid T, Ahmad A. Human insulin: history, recent advances, and expression systems for mass production. Biomedical Research and Therapy. 2021 Sep 30;8(9):4540-61.
- Ribeiro R, Abreu TR, Silva AC, Gonçalves J, Moreira JN. Insights on the formulation of recombinant proteins. Current Applications of Pharmaceutical Biotechnology. 2020:23-54.
| Volume | 02 |
| Issue | 01 |
| Received | February 20, 2024 |
| Accepted | March 19, 2024 |
| Published | March 28, 2024 |